GHK-Cu Wound Healing: Injectable Protocols, Surgical Repair

What is the exact GHK-Cu dosing protocol for wound healing?

Most injectable GHK-Cu wound protocols run 1 to 2 mg subcutaneously. This happens 5 days per week, for 8 to 12 weeks, with a 4-week break between cycles. Post-surgical work often pairs this with BPC-157 at 250 to 500 mcg daily. Topical scar work uses 0.05 to 2% serum instead of injection.

Below is the breakdown by route. "Take GHK-Cu" means three different things, depending on whether you're managing a fresh incision, a stalled tendon repair, or general skin recovery.

The injectable numbers above are the ranges most commonly referenced across practitioner protocols and research write-ups, not a single validated trial dose. Nobody has run a large human RCT to pin down one "correct" injectable schedule. So treat this as a starting framework. Adjust it with a qualified clinician; it's not a fixed prescription.

How long should a GHK-Cu cycle run?

8 to 12 weeks on, 4 weeks off.

That's the standard structure, and there's a real reason for the break. Copper is a trace mineral that your body tightly controls. Continuous high-dose delivery risks pushing your copper levels out of their normal range over time. A 4-week gap lets you check things before starting again. Some longer soft-tissue protocols stretch the active phase to 16 weeks. That goes beyond what most sourcing guides recommend, unless you get a copper and ceruloplasmin blood test first. Benefits from a finished cycle tend to last 2 to 4 months afterward. That's why cycling, instead of running continuously, is the standard here, not a compromise. If you're stacking with a tendon-repair protocol, check how your cycle length matches up with a full BPC-157 dosing protocol running at the same time.

What's the best stack for active recovery?

GHK-Cu earns its place at the end of the repair timeline, not the start. BPC-157 and TB-500 drive the early stages: inflammation and new tissue growth. GHK-Cu takes over once granulation tissue (new tissue filling a wound) starts forming. At that point, the tissue needs organised collagen cross-linking, not just raw growth signals. Running all three together is common in post-surgical protocols. This combo is often called the wolverine stack.

Want a full breakdown of how these three work together after surgery? The BPC-157 and TB-500 post-surgery recovery guide and the wolverine stack protocol both cover this. They go into more depth on injection order and site rotation than fits here.

Injectable, topical, or mesotherapy: which route fits which wound?

Topical GHK-Cu barely crosses intact skin on its own. One study tested microneedles, tiny needles that make small channels in the skin. Skin treated this way let through about 134 nanomoles of peptide over 9 hours. Untreated skin let through almost none (Li et al. 2015). That's the whole reason mesotherapy and post-procedure application exist as separate protocols, instead of just a daily serum.

What evidence actually backs these numbers?

The dosing ranges above come from a mix of animal studies and cell-culture dose-response data. They don't come from one definitive human trial. It matters to know which claim comes from where.

The foundational fibroblast study found something important. Collagen synthesis stimulation started at very low concentrations, as low as 10⁻¹² to 10⁻¹¹ M. It peaked near 10⁻⁹ M. This happened without any rise in cell number (Maquart et al. 1988). That nanomolar potency is why injectable doses can stay in the low-milligram range rather than requiring gram-scale dosing like a bulk supplement. Separately, researchers triggered systemic wound healing in pigs at roughly 1.1 mg per kilogram body weight. That dose sits about 300-fold below the peptide's toxic threshold in that model (Pickart et al. 2012). Scaled to a 75 kg man, that dose sits in the same rough range as the 1 to 2 mg human protocols in use today. This is reassuring, but it's still an extrapolation across species. A broader review linked gene expression data to tissue outcomes. It found that GHK-Cu shifts a meaningful share of the human genome toward younger-tissue patterns. This includes collagen synthesis and antioxidant defense pathways (Pickart and Margolina 2018). None of this replaces a large randomized human trial on injectable dosing, which does not exist yet. Treat the protocol as research-informed, not clinically validated.

How do you reconstitute and store it?

• Use bacteriostatic water, never plain saline. Salt can strip copper off the peptide and cut potency.
• A 50 mg vial mixed with 3 mL bacteriostatic water gives roughly 16.7 mg/mL.
• Draw with a 29-31 gauge insulin syringe for subcutaneous injection.
• Store reconstituted solution refrigerated, away from light, in an amber vial if possible. Copper can catalyze oxidation if exposed to light or heat.
• Use within 2 to 4 weeks of mixing; lyophilized powder keeps far longer, up to a year or more frozen and desiccated.

Get the math wrong here and you either underdose for weeks without realizing it or blow through a vial in days. Our reconstitution mg/mL chart and dose-to-syringe-units chart walk through the conversion math step by step if you want to double check your own numbers.

Where and how do you inject it?

Rotate sites: abdomen (at least an inch from the navel), outer thigh, and back of the upper arm are the standard three.

Space injections an inch or two apart each time to avoid lipodystrophy, the lumpy fat buildup that shows up from repeatedly hitting the same spot. Morning dosing is common practice, on the logic that it aligns with daytime tissue-repair activity, though this is a convention rather than a trial-backed requirement. Inject slowly and steadily into the subcutaneous layer; aspiration isn't necessary for this depth. If you're new to subcutaneous injection technique generally, our guide on oral vs injectable peptide routes covers the basic mechanics before you touch a vial.

What side effects and contraindications matter?

Injection-site redness, warmth, and mild bruising are the most common complaints. These usually clear up within an hour to a day. Topical formulas above 2% strength can cause tingling or flushing on sensitive skin. The risk of systemic copper toxicity is low at standard human doses. Animal studies found a safety margin of about 300 times the effective dose. But some people should avoid this protocol. This includes anyone with a known copper metabolism disorder, an active infection at the injection site, or anyone who is pregnant or breastfeeding. GHK-Cu is not FDA-approved for any medical use. Sourcing quality also varies a lot between suppliers. This is actually a bigger risk than the peptide's own safety profile. Check our recommended sources before buying anything. Never inject material you can't verify.

How do you know the protocol is working, and when do you stop?

Visible change in skin quality or scar texture typically shows up in the 4 to 8 week range, not in days. Animal wound-chamber studies showed collagen remodeling in action. Type I and III collagen expression rose by day 3 and stayed elevated out to day 14. This gives a rough sense of the timeline. But human skin heals on a slower clock than a rat wound chamber. Track photos every 2 weeks rather than daily; day-to-day swings in swelling and redness will hide the real trend. Stop the cycle at the planned 8 to 12 week mark, no matter how things look. Take the 4-week break. Then reassess before deciding whether to run a second cycle.

This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice, and any injectable protocol should be discussed with a qualified clinician before you start.